Celerion is pleased to announce it has been selected by the Foundation for the National Institutes of Health Biomarkers Consortium to provide clinical support for The Beta Cell Project
Celerion
is pleased to announce it has been selected by the
Foundation for the National Institutes of Health (FNIH)
Biomarkers Consortium to provide clinical support for The Beta Cell Project. The Beta Cell Project is a program of studies designed to standardize biomarker measures of beta cell function. Celerion will provide clinical recruitment and conduct to support The Beta Cell Project and assist the FNIH in developing pharmacodynamic measures of beta cell function, with the goal to create industry standards.
The
Biomarkers Consortium
is a public-private biomedical research partnership managed by the FNIH that endeavors to discover, develop, and qualify biological markers (biomarkers) to support new drug development, preventive medicine, and medical diagnostics. The consortium is helping create a new era of personalized medicine, with more highly predictive markers that have an impact during a patient’s illness or lifespan. Their goal is to combine the forces of the public and private sectors to accelerate the development of biomarker-based technologies, medicines, and therapies for the prevention, early detection, diagnosis, and treatment of disease.
“Celerion has continued to invest in and expand our capabilities in metabolic disease to support early Proof-of-Concept studies in the development of diabetes, obesity, metabolic and cardio-metabolic interventions. We are therefore delighted to have been selected to support programs by the FNIH in the area of metabolic disorders,” said Philip Bach, Vice President of Global Clinical Research at Celerion. “The award of this program, and knowing that our contribution will help set industry standards, is recognition of our expertise in this area and the quality of data delivered to clients.”
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.